Elevated levels of LDL cholesterol constitute a major risk factor for Coronary Heart Disease. Treatment decisions are often based on LDL levels as such accurate determination is paramount. Randox have developed a highly specific and accurate direct method to overcome issues with traditional methods of LDL determination.
Crumlin, UK, December 23, 2011 / B3C newswire / - Many laboratories do not analyse LDL directly but simply calculate LDL using the Friedewald equation. The Friedewald equation enables the estimation of LDL cholesterol when triglyceride and HDL levels are known however it has known limitations and is only accurate when triglyceride levels are below 400mg/dl, chylomicrons are absent and the sample does not contain beta-VLDL. Research shows at triglyceride levels more than 250mg/dl over 20% of samples are mis-estimated using Friedewald calculation. Due to these limitations the National Cholesterol Education Programme (NCEP) recommend the direct measurement of LDL cholesterol.
The preferred ultracentrifugation method for LDL determination allows for the selection of specific types of lipoproteins based on their density. Although highly accurate ultracentrifugation methods are not routinely used as they are time and labour consuming, difficult to automate and require specialised equipment which many laboratories do not have.
To overcome the limitations of the Friedewald equation and the ultracentrifugation method Randox have developed a clearance method for the direct measurement of LDL cholesterol. Unlike most commercially available direct LDL assays the Randox advanced reagent formulation enables the rapid clearance of turbidity resulting in reduced interference from bilirubin and triglycerides. The assay works by removing all non-LDL components in the first step of the reaction enabling LDL cholesterol to be accurately and specifically measured in the second step.
Despite being based on the clearance method the detergents and buffering systems used in most other direct assays vary leading to significant differences in assay performance.
Further benefits of the Randox direct clearance LDL assay include excellent correlation to the ultracentrifugation method with a correlation coefficient of 0.99, the availability of fully automated applications for a wide range of clinical analysers, excellent onboard stability and reduced labour, time and consumable costs. Furthermore all reagents are liquid ready to use eliminating the risk of reconstitution errors, potential contamination and bottle to bottle variations.
Randox can also provide high quality reagents covering the full lipid profile including;
Apolipoprotein A-1, A-II, B, C-II, C-III and E
Headquartered in the United Kingdom, Randox Laboratories Ltd. is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical chemistry, cardiology, forensic toxicology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. Our goal is to ‘revolutionise healthcare through continuously improving diagnostic solutions.’ We continue to achieve this year after year due to our commitment and significant re-investment in Research and Development. Our innovative approach to diagnostics allows us to develop revolutionary products, specifically designed to provide more efficient, higher quality and reliable results, ensuring patients receive the right diagnosis at the right time.